Table 2.
Urinary steroid profiling characteristics table following intervention. Data are presented as mean ± s.d.. There was no statistical significance between CWM and surgery at baseline.
| Baseline | 12 Months | |||
|---|---|---|---|---|
| CWM (16) | Surgery (13) | CWM (16) | Surgery (13) | |
| Age (years) | 31.8 ± 7.9 | 32.6 ± 7.4 | ||
| BMI (kg/m2) | 44.7 ± 8.1 | 44.0 ± 7.6 | 44.1 ± 8.8 | 34.0 ± 8.0**,#### |
| ICP (cmCSF) | 32.6 ± 4.8 | 35.2 ± 5.1 | 30.3 ± 5.6 | 23.6 ± 6.6**,#### |
| Sex (female, %) | 100% | 100% | ||
| Fasting insulin (mIU/L) | 17.4 ± 7.6 | 10.7 ± 3.8 | 14.7 ± 6.1$$ | 4.3 ± 4.3*,### |
| HOMA2-IR | 1.9 ± 0.8 | 1.5 ± 0.6 | 1.1 ± 0.4 $$ | 0.4 ± 0.4*, ### |
| Leptin (ng/mL) | 89.3 ± 37.0 | 76.8 ± 32.2 | 79.3 ± 38.8 | 31.9 ± 24.0***, #### |
| IL-6 (pg/mL) | 5.8 ± 2.7 | 6.3 ± 2.1 | 5.4 ± 1.9 | 5.0 ± 2.1 |
| Urine (µg/24 h) | ||||
| 5α-THF | 518 ± 537 | 324 ± 304 | 897 ± 641$ | 403 ± 304* |
| THF | 2305 ± 1708 | 2058 ± 1406 | 2640 ± 1309 | 1967 ± 899 |
| THE | 3435 ± 2121 | 2666 ± 1741 | 5055 ± 2231$ | 3780 ± 1836 |
| Cortisol (F) | 69 ± 51 | 63 ± 47 | 65 ± 27 | 66 ± 25 |
| Cortisone (E) | 90 ± 70 | 73 ± 41 | 118 ± 52 | 106 ± 55 |
| Total GC metabolites | 10057 ± 5881 | 7502 ± 4806 | 14138 ± 6597 | 12195 ± 6026 |
| Derivative measurements | ||||
| 5α-THF+THF/THE | 0.799 ± 0.14 | 0.933 ± 0.22 | 0.699 ± 0.13 | 0.660 ± 0.16#### |
| F/E | 0.812 ± 0.56 | 0.816 ± 0.24 | 0.563 ± 0.11$$$$ | 0.683 ± 0.22# |
| 5α-THF/THF | 0.231 ± 0.10 | 0.188 ± 0.14 | 0.32 ± 0.13$$ | 0.22 ± 0.09 |
*Statistical comparisons between CWM and surgery at 12 months; #Statistical comparison between surgery baseline and surgery 12 months; $Statistical comparison between CWM baseline and surgery 12 months; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
cmCSF, centimeters of cerebrospinal fluid; GC, glucocorticoid; HOMA, homeostatic model assessment; ICP, intracranial pressure; IL-6, interleukin 6; THE, tetrahydrocortisone; THF, tetrahydrocortisol; 5α-THF, 5α-tetrahydrocortisol.
This work is licensed under a